Full-length r-ZEBRA plasmid pET15b (AS 1-245pET15b) was used to transform competent Escherichia coli BL21 (DE3), cultivated in Luria broth (LB) medium, supplemented with ampicillin at 37°C to an optical density (OD) of 0.6-0.8 at 600nm. Following 4 hours (h) of isopropyl β-D-1-thiogalactopyranoside (IPTG) induction at 37°C, the cells were harvested by centrifugation, suspended in 20mM Tris-HCl at pH 8.0 and 250mM NaCl (Tris-NaCl buffer) with 10% glycerol, then lysed by sonication. The resulting bacterial extract was treated with deoxyribonuclease I (DNase I) (Roche Applied Science) for nucleic acid removal. His 6 -tagged proteins were then purified by means of nickel affinity chromatography, washed with a 0.5-1.5 M NaCl gradient and 20mM imidazole, and eluted in 500mM imidazole, 20mM Tris, 75mM KCl, 0.5mM NaCl, and 10% glycerol. All the purification steps were carried out at 4°C with protease inhibitors (complete protease inhibitor mixture; Roche Applied Science).
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Cloning and expression of the recombinant ZEBRA (r-ZEBRA) protein
Full-length r-ZEBRA plasmid pET15b (AS 1-245pET15b) was used to transform competent Escherichia coli BL21 (DE3), cultivated in Luria broth (LB) medium, supplemented with ampicillin at 37°C to an optical density (OD) of 0.6-0.8 at 600nm. Following 4 hours (h) of isopropyl β-D-1-thiogalactopyranoside (IPTG) induction at 37°C, the cells were harvested by centrifugation, suspended in 20mM Tris-HCl at pH 8.0 and 250mM NaCl (Tris-NaCl buffer) with 10% glycerol, then lysed by sonication. The resulting bacterial extract was treated with deoxyribonuclease I (DNase I) (Roche Applied Science) for nucleic acid removal. His 6 -tagged proteins were then purified by means of nickel affinity chromatography, washed with a 0.5-1.5 M NaCl gradient and 20mM imidazole, and eluted in 500mM imidazole, 20mM Tris, 75mM KCl, 0.5mM NaCl, and 10% glycerol. All the purification steps were carried out at see table 2 ) (3,700ng/mL / 34,000 copies/ml -2,300 ng/ml / 1,600 copies/ml -1,900ng/ml / 5,000 copies/ml, respectively), and conducted a neutralization test by mixing each serum sample (1/10 dilution) with increasing concentrations of AZ130 mAb at a volume ratio of 1:1. 67, 734-742 (1993) .
